company background image
HIMS

Hims & Hers HealthNYSE:HIMS Stock Report

Market Cap

US$1.4b

7D

-4.9%

1Y

-35.4%

Updated

30 Nov, 2021

Data

Company Financials +
HIMS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

HIMS Stock Overview

Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals.

Hims & Hers Health Competitors

Cigna

NYSE:CI

US$66.2b

1Life Healthcare

NasdaqGS:ONEM

US$3.2b

Amazon.com

NasdaqGS:AMZN

US$1.8t

Teladoc Health

NYSE:TDOC

US$17.5b

Price History & Performance

Summary of all time highs, changes and price drops for Hims & Hers Health
Historical stock prices
Current Share PriceUS$6.80
52 Week HighUS$25.40
52 Week LowUS$6.57
Beta-0.058
1 Month Change-12.82%
3 Month Change-13.71%
1 Year Change-35.36%
3 Year Changen/a
5 Year Changen/a
Change since IPO-30.61%

Recent News & Updates

Nov 30

Hims & Hers: Great Business, Greater Opportunity

As the lowest cost provider in a growth sector, Hims has the potential to become a major player in the future of Telemedicine. Hims has increased sales at a CAGR of over 77% since inception. There is still ample opportunity for further revenue growth as the market is large and growing. The company has strong branding, customer loyalty, increasing sales, a large gross margin, and a growing subscriber base. Margins may shrink in the future as the company incurs a mix shift towards lower margin distributer selling and less via direct to consumer. This has not been mentioned to substantially affect margins, but it is a possibility. An important risk to note is Telemedicine is a low barrier to entry industry and as a result, Hims could face increased competition in the future.

Oct 06

Hims & Hers Health Stock: An Opportunity After Large Sell-Off

Telehealth concern Hims & Hers Health, Inc. has experienced an approximate 65% share price decline since February 2021 even though it raised its FY21 revenue outlook twice. Despite its impressive growth, many are skeptical it can expand its business model outside the treatment of stigmatized conditions. With few barriers preventing deep-pocketed competitors from entering its space, a recognized brand, and insider buying, this busted IPO merited a deeper dive. A full investment analysis is provided in the paragraphs below.

Sep 23

Hims & Hers Health: An Amazing Bargain Price For This High Growth Stock

As high-growth names start to make a comeback, investors would do well to consider this healthcare stock. Hims is likely to smash through its 30% revenue growth rate expectations in 2022. At just 5x next year's revenues, for a company that isn't that unprofitable, this stock is worthwhile buying.

Aug 25

Time To Buy Hims & Hers

Hims & Hers is a consumer healthcare brand targeting young digitally native consumers and stigmatized disorders. Hims & Hers management is building a track record of strong growth, scalability, and underpromising and overdelivering. Hims & Hers trades is close to all-time-lows.

Shareholder Returns

HIMSUS HealthcareUS Market
7D-4.9%-0.4%-0.9%
1Y-35.4%20.7%23.3%

Return vs Industry: HIMS underperformed the US Healthcare industry which returned 20.7% over the past year.

Return vs Market: HIMS underperformed the US Market which returned 23.3% over the past year.

Price Volatility

Is HIMS's price volatile compared to industry and market?
HIMS volatility
HIMS Average Weekly Movement8.5%
Healthcare Industry Average Movement6.3%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.3%

Stable Share Price: HIMS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: HIMS's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013181Andrew Dudumhttps://www.forhims.com

Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care.

Hims & Hers Health Fundamentals Summary

How do Hims & Hers Health's earnings and revenue compare to its market cap?
HIMS fundamental statistics
Market CapUS$1.40b
Earnings (TTM)-US$81.73m
Revenue (TTM)US$228.65m

6.1x

P/S Ratio

-17.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HIMS income statement (TTM)
RevenueUS$228.65m
Cost of RevenueUS$54.36m
Gross ProfitUS$174.29m
ExpensesUS$256.02m
Earnings-US$81.73m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.40
Gross Margin76.23%
Net Profit Margin-35.74%
Debt/Equity Ratio0.0%

How did HIMS perform over the long term?

See historical performance and comparison

Valuation

Is Hims & Hers Health undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HIMS ($6.8) is trading below our estimate of fair value ($23.33)

Significantly Below Fair Value: HIMS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HIMS is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: HIMS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HIMS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HIMS is overvalued based on its PB Ratio (3.9x) compared to the US Healthcare industry average (2.8x).


Future Growth

How is Hims & Hers Health forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

22.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HIMS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HIMS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HIMS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HIMS's revenue (29% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: HIMS's revenue (29% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HIMS is forecast to be unprofitable in 3 years.


Past Performance

How has Hims & Hers Health performed over the past 5 years?

-223.8%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: HIMS is currently unprofitable.

Growing Profit Margin: HIMS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if HIMS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare HIMS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HIMS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (32.5%).


Return on Equity

High ROE: HIMS has a negative Return on Equity (-23.01%), as it is currently unprofitable.


Financial Health

How is Hims & Hers Health's financial position?


Financial Position Analysis

Short Term Liabilities: HIMS's short term assets ($274.2M) exceed its short term liabilities ($52.5M).

Long Term Liabilities: HIMS's short term assets ($274.2M) exceed its long term liabilities ($12.4M).


Debt to Equity History and Analysis

Debt Level: HIMS is debt free.

Reducing Debt: HIMS had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HIMS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if HIMS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Hims & Hers Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HIMS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HIMS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HIMS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HIMS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HIMS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Andrew Dudum (32 yo)

0.83

Tenure

US$26,575,832

Compensation

Mr. Andrew Dudum is Chairman of the Board and Chief Executive Officer at Hims & Hers Health, Inc. since January 20, 2021. He Co-Founded Hims & Hers Health, Inc. in 2017. He is Co-founded of Hims, Inc. and...


CEO Compensation Analysis

Compensation vs Market: Andrew's total compensation ($USD26.58M) is above average for companies of similar size in the US market ($USD3.67M).

Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: HIMS's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: HIMS's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Hims & Hers Health, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Hims & Hers Health, Inc.
  • Ticker: HIMS
  • Exchange: NYSE
  • Founded: 2013
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$1.403b
  • Shares outstanding: 203.91m
  • Website: https://www.forhims.com

Number of Employees


Location

  • Hims & Hers Health, Inc.
  • 2269 Chestnut Street
  • Suite 523
  • San Francisco
  • California
  • 94123
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/30 00:31
End of Day Share Price2021/11/29 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.